zanubrutinib
FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma
The FDA granted accelerated approval to Brukinsa with Gazyva for relapsed or refractory follicular lymphoma after ...
MARCH 9, 2024
Brukinsa Granted Accelerated Approval for Treatment of R/R MZL
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adults with relapsed or refractory ...
OCTOBER 14, 2021
Load more